• Explore /
  • Poster
  • / Long-term follow-up for duration of response (DoR) after weekly <em>nab</em>-sirolimus in patients with advanced malignant perivascular epithelioid cell tumors (PEComa): Results from a registrational open-label phase II trial, AMPECT.

Long-term follow-up for duration of response (DoR) after weekly nab-sirolimus in patients with advanced malignant perivascular epithelioid cell tumors (PEComa): Results from a registrational open-label phase II trial, AMPECT.

Abstract Video & Slides Poster

Authors

null

Andrew J. Wagner

Dana-Farber Cancer Institute, Boston, MA

Andrew J. Wagner , Vinod Ravi , Richard F. Riedel , Kristen N. Ganjoo , Brian Andrew Van Tine , Rashmi Chugh , Lee D. Cranmer , Erlinda Maria Gordon , Jason L. Hornick , David J. Kwiatkowski , Heng Du , Berta Grigorian , Anita N. Schmid , Shihe Hou , Katherine Harris , Neil Desai , Mark Andrew Dickson

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Soft Tissue Tumors

Clinical Trial Registration Number

NCT02494570

Citation

J Clin Oncol 38: 2020 (suppl; abstr 11516)

DOI

10.1200/JCO.2020.38.15_suppl.11516

Abstract #

11516

Poster Bd #

404

Abstract Disclosures

Similar Posters

First Author: Gopa Iyer

First Author: Dustin A. Deming

First Author: Gopa Iyer

First Author: Mark Andrew Dickson